AU2020229374A1 - Compositions for treating osteosarcoma and methods of use - Google Patents

Compositions for treating osteosarcoma and methods of use Download PDF

Info

Publication number
AU2020229374A1
AU2020229374A1 AU2020229374A AU2020229374A AU2020229374A1 AU 2020229374 A1 AU2020229374 A1 AU 2020229374A1 AU 2020229374 A AU2020229374 A AU 2020229374A AU 2020229374 A AU2020229374 A AU 2020229374A AU 2020229374 A1 AU2020229374 A1 AU 2020229374A1
Authority
AU
Australia
Prior art keywords
antibody
sequence
seq
fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020229374A
Other languages
English (en)
Other versions
AU2020229374A2 (en
Inventor
Sumin GU
Jean Jiang
Manuel Riquelme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU2020229374A1 publication Critical patent/AU2020229374A1/en
Publication of AU2020229374A2 publication Critical patent/AU2020229374A2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020229374A 2019-02-28 2020-02-28 Compositions for treating osteosarcoma and methods of use Pending AU2020229374A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811938P 2019-02-28 2019-02-28
US62/811,938 2019-02-28
PCT/US2020/020343 WO2020176844A1 (en) 2019-02-28 2020-02-28 Compositions for treating osteosarcoma and methods of use

Publications (2)

Publication Number Publication Date
AU2020229374A1 true AU2020229374A1 (en) 2021-08-19
AU2020229374A2 AU2020229374A2 (en) 2021-10-21

Family

ID=72238666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020229374A Pending AU2020229374A1 (en) 2019-02-28 2020-02-28 Compositions for treating osteosarcoma and methods of use

Country Status (7)

Country Link
US (1) US20220162298A1 (enExample)
EP (1) EP3931222A4 (enExample)
JP (1) JP7710374B2 (enExample)
CN (2) CN113574070B (enExample)
AU (1) AU2020229374A1 (enExample)
CA (1) CA3131925A1 (enExample)
WO (1) WO2020176844A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277928A4 (en) * 2021-01-13 2025-03-19 Board of Regents, The University of Texas System COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS AND JOINT AND TENDON DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091903A1 (en) * 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2015027120A1 (en) * 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途

Also Published As

Publication number Publication date
JP2022522011A (ja) 2022-04-13
AU2020229374A2 (en) 2021-10-21
EP3931222A1 (en) 2022-01-05
WO2020176844A1 (en) 2020-09-03
JP7710374B2 (ja) 2025-07-18
EP3931222A4 (en) 2023-11-01
CN113574070A (zh) 2021-10-29
CN119950706A (zh) 2025-05-09
CN113574070B (zh) 2025-02-25
CA3131925A1 (en) 2020-09-03
US20220162298A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US12503500B2 (en) Connexin 43 (Cx43) hemichannel-binding antibodies
EP2970494B1 (en) Her3 specific monoclonal antibodies for diagnostic and therapeutic use
US11512141B2 (en) Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment
JP7710374B2 (ja) 骨肉腫を治療するための組成物及び使用方法
US10759857B2 (en) JAM-C antibodies and methods for treatment of cancer
US10729781B2 (en) LGR4 specific monoclonal antibodies and methods of their use
US20230092390A1 (en) Human 4-1bb agonist antibodies and methods of use thereof
HK40062936B (en) Compositions for treating osteosarcoma and methods of use
HK40100475A (en) Connexin (cx)43 hemichannel-binding antibodies and uses thereof
HK40062936A (en) Compositions for treating osteosarcoma and methods of use
WO2025090760A1 (en) Antibodies specific to scube3 and methods of use
HK1262261B (en) Connexin (cx) 43 hemichannel-binding antibodies and uses thereof
HK1213584B (en) Jam-c antibodies and methods for treatment of cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 SEP 2021 AND 4 OCT 2021